| Acquired by | Johnson & Johnson |
| Price | $1B |
| Date | 6/13 |
| Website | aragonpharmaceuti... |
| Category | BioTech |
| Phone | 858-369-7600 |
| info@aragonpharma... | |
| Employees | |
| Founded | 2009 |
| Description | Hormone-resistant Cancer Treatment |
| TOTAL | $122M |
| FUNDING TOTAL | $122M |
| Series A, 5/09 The Column Group OrbiMed Advisors | $8M |
| Series B, 4/10 The Column Group Aisling Capital OrbiMed Advisors | $22M |
| Series C, 3/12 Topspin Partners | $42M |
| Series D, 10/12 venBio Aisling Capital OrbiMed Advisors The Column Group | $50M |
Aragon Pharmaceuticals is a discovery-stage small molecule company focused on therapeutics for the treatment of hormone-resistant cancers, with an initial focus on prostate and breast cancer.